This trial is evaluating whether Acalabrutinib will improve 1 primary outcome and 5 secondary outcomes in patients with Non-Hodgkin's Lymphoma (NHL). Measurement will happen over the course of every 2 cycles.
This trial requires 132 total participants across 1 different treatment group
This trial involves a single treatment. Acalabrutinib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"Signs of lymphoma include malaise, swollen lymph nodes, swollen and tender spleen, pain or tenderness on one side of the body or sudden change in the pattern of lymph-node pain, a change of skin color or a lump in the neck. However, the full range of symptoms and signs may not occur in all patients with lymphoma." - Anonymous Online Contributor
"Findings from a recent study shows that lymphoma is responsible for the greatest number of cancer deaths in the United States. While it is an uncommon cause of death among whites, it is much more common in Hispanics, and Blacks. Prevention is paramount. It is estimated that the United States has 20 million people with lymphoma each year. We need to educate our children, who are the next generation of doctors and nurses. They need to be aware of the importance of early onset screening for lymphoma. Our country has the highest number of foreign born individuals in the United States, which makes lymphoma especially dangerous. Our nation also has the highest number of African Americans in both the United States and Europe." - Anonymous Online Contributor
"There are about 15 types of lymphoma. The prevalence of these diseases ranges widely. They are highly variable in their clinical presentations. Most lymphomas are curable. More knowledge of immunohistochemistry and improved classification of lymphoblastic and other lymphoid neoplasms are increasing the ability to define these diseases and to assess the best treatment to offer them." - Anonymous Online Contributor
"Recent findings are not hopeful and chemotherapy should continue to be the primary treatment option for non-Hodgkin's lymphoma, even where it has been found to be curable by surgery or radiotherapy." - Anonymous Online Contributor
"Acalabrutinib is a novel multi-targeted Bcr-Abl tyrosine kinase inhibitor, approved on the basis of its efficacy in relapsed or refractory relapsed acute lymphoblastic leukemia, with or without Bcr-Abl kinase gene mutations, in adults and children ≥12 years of age. In a phase II study, the efficacy in treating B-cell chronic lymphocytic leukemia was demonstrated in patients with a Bcr-Abl (V560L) mutation (95% of patients) and patients with no Bcr-Abl kinase gene mutation (88% of patients) and in phase III trial of refractory systemic B-cell CLL." - Anonymous Online Contributor
"Our survey found that most of the lymphoma is caused by infections, with (perhaps) greater contribution of viral than bacterial infection. Immunosuppression appears to increase the risk of infection-induced lymphomatous transformation. In a recent study, findings may help to guide therapeutic and preventive strategies for lymphoma, but the data of the literature on the associations between viral load and the risk of developing lymphoma is inconclusive. We still have to explore in depth the nature and dynamics of viral interactions with the immune system and with the cellular signalling pathways that are defective in lymphoma." - Anonymous Online Contributor
"Acalabrutinib is a clinically active agent for the treatment of mantle cell lymphoma in adults. Based on these data, acalabrutinib has a recommended dose of 800 mg once daily." - Anonymous Online Contributor
"The American Cancer Society estimates that there will be over 40,000 people dying of lymphoma in 2015, making it the ninth-most common cancer, in the US." - Anonymous Online Contributor
"Acalabrutinib is a promising, broad-spectrum Bruton’s tyrosine kinase inhibitor with a novel mechanism of action of preferential inhibition of the Btk catalytic activity. This novel mechanism of action allows acalabrutinib to selectively suppress tyrosine kinase activity while suppressing Btk catalytic activity. As such, it is a potential antitumor agent with broad therapeutic potential as a single-agent and combined with other agents to treat a wide variety of cancers." - Anonymous Online Contributor
"ACM is well tolerated with a high rate of completion of courses of treatment. There were few serious adverse events in this study. There have been no deaths resulting from ACM, to date." - Anonymous Online Contributor